Wiki Article
Menarini
Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net
| Type | Limited liability company |
|---|---|
| Industry | Pharmaceutical Health care and diagnostics[1] |
| Founded | 1886 in Naples |
| Founder | Archimede Menarini |
| Headquarters | , Italy |
Area served | Worldwide |
Key people |
|
| Revenue | € 4.88 billion (2025)[6] |
Number of employees | 17,800 (2025)[6] |
| Website | https://www.menarini.com/ |
The Menarini Group is an Italian pharmaceutical company. Its headquarters is in Florence, Tuscany, and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for cardiovascular diseases, oncology, pain/inflammation, asthma and anti-infectives. Menarini's research activities are carried out through Menarini Ricerche, which deals with all R&D activities, from the creation of new projects to drug registration. Its Menarini Biotech follows the creation of a biotechnological drug from the very early stages of research, through to the pilot scale and up to industrial production. The Group's Menarini Diagnostics division is a healthcare company with a worldwide network of affiliates partners and distributors focused on diabetes, haematology, clinical chemistry, urinalysis, and immunology. In 2025, the company had 17,800 employees worldwide.[6]
Massimiliana Landini Aleotti and her three children inherited the company, valued at US$11.6 billion, following the death of her husband in May 2014.[7]
History
[edit]
Menarini was founded in 1886[8][9] in the small laboratory of the Farmacia Internazionale in Naples, founded by Doctor Archimede Menarini.[10][11] Alongside its regular galenic production, the first medicines distributed under the Menarini brand were soon introduced: Metarsile,[12] a restorative based on iron phospho-methylarsinate, produced until the 1960s, and Euzymina,[13] a solution of digestive ferments with lecithin indicated for the treatment of digestive disorders.[11][9] In 1915, the business was moved from Naples to Florence, due to its proximity to numerous glassworks.[12][8]
In the 1960s, it acquired the Spanish laboratory Puig Sala, now Laboratorios Menarini, founded in 1924 in Barcelona.[14][15] In 1972 the headquarters moved from Barcelona to Badalona, expanding the facilities to 15,000 m². Menarini Spain and its subsidiaries in Central America and the Caribbean focus on research and development of medicines for cardiovascular diseases, anti-inflammatory drugs and pain relief.[16][17]
In 1976, Menarini Diagnostics was established, specialising in self-monitoring systems for glucose and in laboratory analysis. The division initially operated only in Italy as a distributor of laboratory systems; in the 1980s it opened a technology department with a quality control laboratory and its first production facility. From 1984 onwards, self-monitoring systems for diabetes were added to its laboratory instrumentation.[18][17] In 1976, the Fondazione Internazionale Menarini was also established to promote research and knowledge in the fields of biology, pharmacology and medicine, economics and the humanities, and it organises international congresses with particular attention to medical disciplines.[19][20]
In 1978, the Menarini Group acquired Malesci, a Florentine pharmaceutical company founded in 1850.[21][22]
In 1982, the first affiliate in Central America and the Caribbean was established. The headquarters is located in Guatemala, where a production plant operates.[17]
Between 1983 and 1984, the company acquired Guidotti of Pisa,[23] Lusofarmaco of Milan and FIRMA.[22][24] In 1992, the German company Berlin Chemie (founded in 1890) joined the group, opening up a new market in Central and Eastern Europe.[9] In the same year, the Menarini France subsidiary was established.[25] The Research Toxicology Center (RTC) was founded in 1987 in Pomezia,[24] followed in 1992 by the Menarini Research Campus and in 2003 by the Menarini Biotech biotechnology plant.[17]
In 1993, the L'Aquila plant was inaugurated.[26] In 1994, Menarini entered the Indian market through a partnership with Raunaq Industries[27] and in the same year opened its OTC (over-the-counter medicines) division,[28] followed in 2001 by the acquisition of IE Ulagay,[29] a former Turkish laboratory founded in 1903,[30] and the establishment of its affiliate in Argentina, with a quality control laboratory in Buenos Aires.
In 2006, the Menarini-von Heyden production plant was inaugurated in Dresden[31] and in 2008 the Menarini Mexico affiliate was established.[32] In 2011, Invida was acquired and became Menarini Asia-Pacific, with a presence in numerous South Asian countries.[33][34]
In 2013, the Italian start-up Silicon Biosystems, winner of the 2012 "Premio Leonardo", specialising in rare cell research down to single-cell precision, was acquired and became Menarini Silicon Biosystems.[35] The latter subsequently acquired all corporate activities related to the CellSearch system.[36]
In 2014, Menarini Biomarkers was established for the research and development of biomarkers for prenatal diagnosis without amniocentesis, as well as in the field of lung and ocular cancers.[37] In the same year, the group opened a new pharmaceutical production plant in Kaluga (Russian Federation).[38]
In March 2018, the company announced the appointment of a new board of directors, marking the first time that an external manager, Eric Cornut, had taken on the role of chairman.[39] Cornut, a Swiss national from Basel with a master's degree obtained in California, spent 20 years at Novartis and for two years, until April 2017, served as Director General of the EFPIA (European Federation of Pharmaceutical Industries and Associations).[40] On 12 September 2019, the board of directors appointed Elcin Barker Ergun as chief executive officer of the company.[41]
In 2020, Menarini developed a rapid COVID-19 test amid the COVID-19 pandemic in Italy, capable of giving a result in just 20 minutes.[42] The same year the group acquired Stemline Therapeutics, a United States-based biopharmaceutical company then listed on the Nasdaq, specialising in the development of innovative oncology therapies.[43] As of 2025, Menarini Stemline has obtained approval from the main regulatory authorities worldwide for three oncology drugs.[44][45][46][47]
Operations
[edit]Research and development
[edit]The group is involved in the entire drug development cycle, from the initial design of new projects to their authorization and commercialization. Programs developed across the group’s nine research centers focus on cardiovascular diseases, oncology, and infectious diseases.[48]
Since 1986, Menarini has operated in the field of biotechnology in Italy at its Pomezia site.[24][49]
Production
[edit]The Menarini Group operates 18 manufacturing plants worldwide: two facilities in Florence (Florence–Sette Santi[50] and Florence–Scandicci), two in Pisa (Lusochimica and Menarini Manufacturing),[23] Lomagna,[51] Casaletto Lodigiano,[52] L'Aquila,[26] Badalona (Spain),[16] two facilities in Berlin,[53] Dresden,[54] Topkapı – Istanbul,[55] Shannon (Ireland),[56] Jakarta,[57] Kaluga (Russia),[38] and Guatemala City.[58]
In 2024, the group produced a total of 609 million units.[59]
Diagnostics
[edit]The group’s subsidiary Menarini Diagnostics specializes in the production of glucose self-monitoring sensors, reagents, and laboratory diagnostics. The company operates internationally.[60][61][62]
Distribution network
[edit]As of 2025, through direct subsidiaries and local distributors, Menarini operates in 140 countries.[6]
Financial data
[edit]In 2025, the company's revenue totaled 4.88 billion euros, representing a 6.2% increase compared to 2024. At the end of the year, the group had 17,800 employees.[6]
Fair Play Menarini International Award
[edit]Since 2011, Menarini has been the title sponsor of the Fair Play Menarini International Award, which since 1997 has recognised acts of loyalty and fairness performed by leading figures in sport.[63][64] Since 2021, the award has been organised independently by Menarini through the Fair Play Menarini Foundation.[65] Each year, the athletes and sports figures who receive the award become Fair Play Menarini ambassadors, serving as symbols of sporting achievements carried out in the spirit of fair play and respect for the rules.[66]
Social causes
[edit]Pediatricians network against child abuse
[edit]"Paediatric network against ill-treatment of minors" has been launched and supported by the pharmaceutical company, Menarini, together with it:Telefono Azzurro, the Italian Federation of Paediatricians, and the Association of Italian Paediatric Hospitals, has grown beyond Italian borders.[67]
The project originated in Italy and is the first of its kind in the world. It was launched in May 2016 in the city of Florence and is supported by Menarini with an investment of one million euro. It foresees the creation of a network of 15,000 paediatricians and general practitioners deployed over the entire Italian territory who act as 'sentinels' in the fight against child abuse. These physicians, who have been 'trained' on the skills needed to recognise the unexpressed 'sentinel' warning signs of child abuse, shall in turn become reference people for their colleagues on a local level, providing qualified information and advice. This project is for the creation of an anti-abuse network.[68]
On 18 October 2016 the project was presented in Tirana to more than 500 paediatricians, not only from the Balkans but also from other countries such as Romania, Switzerland, Turkey and others.[69]
Social housing renovation project
[edit]The Menarini pharmaceutical group is committed to the recovery of several social housing owned by the municipality of Florence. So far the apartments recovered are 20 and have been assigned to families of small and medium size. The surfaces of the delivered housing range from 50 to 70 square metres each. The first agreement between the Menarini Group and the City of Florence was presented on 16 July 2013 by the mayor of Florence, Matteo Renzi and Lucia Aleotti, President of the Menarini pharmaceutical group.[70]
On 18 January 2014 the Menarini Group has delivered the first three of 10 apartments, located in Via Rocca Tedalda, in the south side of Florence.[71]
On 27 March 2014, the keys of the last 7 houses of the first edition of the project were delivered.[72]
On 12 December 2014 it was announced the second edition of the project of social housing redevelopment in Palazzo Vecchio by Mayor Dario Nardella, the President and the vice-chairman of the pharmaceutical group Menarini Lucia and Alberto Giovanni Aleotti.[73]
On 21 April 2015, 10 apartments renovated from Menarini were delivered to 10 needy families in the city.[74]
On 30 November 2015 it was announced the third edition of the project.[75]
On 17 June 2016 the Menarini Group and the City of Florence have handed over the keys of 10 renovated houses to those families included in the social rankings of the city.[76]
Criticism
[edit]The Menarini Group continued its operations in Russia despite the international sanctions imposed following Russia's invasion of Ukraine.[77] The company faced criticism from organizations promoting corporate accountability and ethical practices in regions affected by geopolitical conflicts.[78]
See also
[edit]Publications
[edit]- "Handling with missing data in clinical trials for time-to-event variables" (PDF). PharmaSUG. SP02: 1–9. 2014. Retrieved 2016-11-07.
- "Ranolazine Reduces The Late Recurrences Of Atrial Fibrillation. An Exploratory Analysis Of The Raffaello Study". Treatment of Arrhythmias: Pharmacological-atrial Fibrillation. 130. November 2014. Retrieved 2016-11-07.
- "MEN1112, a Novel Humanized De-Fucosylated Monoclonal Antibody with High Affinity and Specificity for Bst1/CD157 Antigen and Enhanced CD16 Binding". 56th ASH Annual Meeting and Exposition, S. Francisco (CA). 124: 3607. December 2014. Retrieved 2016-11-07.
- "Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen". 56th ASH Annual Meeting and Exposition, S. Francisco (CA). 124: 2235. December 2014. Retrieved 2016-11-07.
- "Prophylaxis with Febuxostat in comparison to Allopurinol reduces exposure to uric acid in patients at intermediate to high risk of tumor lysis syndrome: results of the Florence study". 19th Congress of the European Hematology Association, Milano. June 2014. Retrieved 2016-11-07.
- Baldini, Simone; Rossi, Cristina; Spina, Michele; Federico, Massimo; Nagy, Zsolt; Jordan, Karin; Aurer, Igor; Ribera, Josep-Maria; Borsaru, Gabriela; Glushko, Nataliia; Grosicki, Sebastian; Pristupa, Alexander; Bosi, Alberto; Rego, Eduardo M.; Nizzardo, Andrea; Scartoni, Simona; Scordari, Alessandra; Matera, Mariagiuseppa; Maggi, Carlo Alberto; Capriati, Angela; Simonelli, Cecilia (December 2014). "Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study". Blood. 124 (21): 5979. doi:10.1182/blood.V124.21.5979.5979. Retrieved 2016-11-07.
- "A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study". Clin Oncol. 32. June 2014. Retrieved 2016-11-07.
- Tack, Jan F.; Capriati, Angela; Schumacher, Kai; Ligas, Franca; Ott, Kerstin; Tonini, Giulia; Scartoni, Simona; Otranto, Isabella; Nuti, Alessandra; Maggi, Carlo Alberto (May 2014). "Sa1080 Concordance Among Outcome Variables Assessing the Response to Treatment With Ibodutant in Irritable Bowel Syndrome With Diarrhea (IBS-D; the IRIS-2 Study)". Gastroenterology. 146 (5): 194. doi:10.1016/s0016-5085(14)60684-3. Retrieved 2016-11-07.
- Oliveras, A; Armario, P; Lucas, S; de la Sierra, A (March 2014). "Blood pressure control is similar in treated hypertensive patients with optimal or with high-normal albuminuria". American Journal of Hypertension. 27 (9): 1185–1190. doi:10.1093/ajh/hpu039. PMID 24646879. Retrieved 2016-11-07.
- Ceriotti, F; Kaczmarek, E; Guerra, E; Mastrantonio, F; Lucarelli, F; Valgimigli, F; Mosca, A (December 2014). "Comparative Performance Assessment of Point-of-Care Testing Devices for Measuring Glucose and Ketones at the Patient Bedside". Journal of Diabetes Science and Technology. 9 (2): 268–77. doi:10.1177/1932296814563351. PMC 4604596. PMID 25519295.
- Allais, G; Tullo, V; Cortelli, P; Barbanti, P; Valguarnera, F; Sette, G; D'Onofrio, F; Curone, M; Zava, D; Pezzola, D; Reggiardo, G; Omboni, S; Frediani, F; Bussone, G; Benedetto, C (May 2014). "EHMTI-0052. Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura". The Journal of Headache and Pain. 35 (1): 107–113. doi:10.1007/s10072-014-1751-3. PMC 4035546. PMID 24867846.
- Bucci, M; Vellecco, V; Cantalupo, A; Brancaleone, V; Zhou, Z; Evangelista, S; Calderone, V; Papapetropoulos, A; Cirino, G (February 2014). "Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition". Cardiovascular Research. 102 (1): 138–147. doi:10.1093/cvr/cvu026. PMID 24501330. Retrieved 2016-11-07.
- Momi, S; Caracchini, R; Falcinelli, E; Evangelista, S; Gresele, P (February 2014). "Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis". Arteriosclerosis, Thrombosis, and Vascular Biology. 34 (4): 820–829. doi:10.1161/atvbaha.114.303290. PMID 24558107. Retrieved 2016-11-07.
- Mainardi, F; Maggioni, F; Pezzola, D; Zava, D; Zanchin, G (January 2014). "Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study". The Journal of Pain. 333 (4): 388–394. doi:10.1016/j.jpain.2013.12.006. hdl:11577/3178223. PMID 24412801. Retrieved 2016-11-07.
- Agabiti-Rosei, E; Manolis, A; Zava, D; Omboni, S (January 2014). "Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients". Advances in Therapy. 31 (2): 217–233. doi:10.1007/s12325-013-0090-8. PMC 3930838. PMID 24415271.
- Tullo, V; Valguarnera, F; Barbanti, P; Cortelli, P; Sette, G; Allais, G; d'Onofrio, F; Curone, M; Zava, D; Pezzola, D; Benedetto, C; Frediani, F; Bussone, G (December 2013). "Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study". Cephalalgia. 34 (6): 434–445. doi:10.1177/0333102413515342. PMID 24363238. Retrieved 2016-11-07.
- Saracco, MG; Allais, G; Tullo, V; Zava, D; Pezzola, D; Reggiardo, G; Omboni, S; Benedetto, C; Bussone, G; Aguggia, M (May 2014). "Efficacy of frovatriptan and other triptans in the treatment of acute migraine of normal weight and obese subjects: a review of randomized studies". Neurological Sciences. 35 (1): 115–119. doi:10.1007/s10072-014-1752-2. PMID 24867847. S2CID 20224729. Retrieved 2016-11-07.
- Traini, C; Faussone-Pellegrini, MS; Evangelista, S; Mazzaferro, K; Cipriani, G; Santicioli, P; Vannucchi, MG (January 2015). "Inner and outer portions of colonic circular muscle: ultrastructural and immunohistochemical changes in rat chronically treated with otilonium bromide". PLOS ONE. 9 (8) e103237. doi:10.1371/journal.pone.0103237. PMC 4133200. PMID 25122192.
- Terzuoli, E; Meini, S; Cucchi, P; Catalani, C; Cialdai, C; Maggi, CA; Giachetti, A; Ziche, M; Donnini, S (January 2014). "Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation". PLOS ONE. 9 (1) e84358. Bibcode:2014PLoSO...984358T. doi:10.1371/journal.pone.0084358. PMC 3879294. PMID 24392129.
References
[edit]- ^ "Menarini Diagnostics lancia il test molecolare che distingue il Covid-19 da influenza in 20 minuti". La Stampa (in Italian). 2020-12-17.
- ^ Giorgio Del Re (6 June 2020). "Gruppo Menarini: "Siamo un'azienda orgogliosamente italiana, vogliamo contribuire al rilancio del Paese"". The Post Internazionale (in Italian).
- ^ "Menarini: Elcin Barker Ergun Group CEO". Adnkronos. 14 December 2020. Archived from the original on 2021-04-25.
- ^ "Menarini, Cueni joins the group's board". Il Messaggero (in Italian). 2026-05-09. Retrieved 2026-05-14.
- ^ "Carlo Colombini entra nel Cda del Gruppo Menarini - Salute & Benessere". Ansa (in Italian). 29 October 2018.
- ^ a b c d e Ernesto Diffidenti (2026-03-07). "Menarini cresce in tutto il mondo e il fatturato vola a quota 4,88 miliardi (+6,2%)". Il Sole 24 Ore (in Italian). Retrieved 2026-03-09.
- ^ "Massimiliana Landini Aleotti". Forbes. Retrieved 1 February 2016.
- ^ a b "Tutto nasce da una antica Farmacia a Napoli nel 1886". ANSA (in Italian). 13 March 2017. Retrieved 17 April 2018.
- ^ a b c "Menarini, la rivoluzione di Alberto che brevettò la farmacia". Il Messaggero (in Italian). 1 December 2016. Retrieved 27 February 2026.
- ^ Luca Anselmi; Nicola Lattanzi, eds. (2017). Il family business made in Tuscany (in Italian). Franco Angeli Edizioni. p. 438. ISBN 9788891747228. Retrieved 27 February 2026.
- ^ a b "Menarini a Firenze: la storia". 2015-03-04. Retrieved 27 February 2026.
- ^ a b Carla Massi (18 March 2015). "Menarini, cento anni d'Italia in pillole". Il Messaggero (in Italian). Archived from the original on 2023-04-29. Retrieved 27 February 2026.
- ^ La medicina giusta - Viaggio fotografico nell’industria farmaceutica in Italia (PDF) (in Italian). ANSA. p. 85.
- ^ Mar Galtés Barcelona (24 June 2016). "Kymos crece con la biotec". La Vanguardia (in Spanish). Retrieved 27 February 2026.
- ^ Josep-Eladi Baños; Sílvia Fernández; Fèlix Bosch (2007). "El naixement de la indústria farmacèutica a Catalunya (I): El marc històric de la seva aparició". Annals de Medicina (in Catalan). 90: 54–59.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ a b Ester Maragò (10 September 2018). "Farmaceutica. Menarini Spagna. Terapia del dolore, R&S e formazione continua: un "successo" del made in Italy". Quotidianosanita.it (in Italian). Retrieved 27 February 2026.
- ^ a b c d Eugenio Caruso. "Menarini, la prima casa farmaceutica italiana" (in Italian). Retrieved 18 February 2026.
- ^ "Menarini Diagnostics – Company Profile". Retrieved 27 February 2026.
- ^ Francesco Perrini (2011). Social Venture Capital & Venture Philanthropy (in Italian). Egea. ISBN 9788823872073. Retrieved 27 February 2026.
- ^ "Fondazione Internazionale Menarini" (in Italian). Retrieved 27 February 2026.
- ^ Sergio Meda. "I Malesci. Storie Storie di Granducato e di Regno d'Italia" (PDF) (in Italian). Retrieved 18 February 2026.
- ^ a b "Menarini, A. industrie farmaceutiche" (in Italian). Retrieved 18 February 2026.
- ^ a b Margherita Lopes (13 May 2025). "Menarini a Pisa fa poker: le 4 aziende del Gruppo e il caso materie prime". Fortune Italia (in Italian). Retrieved 18 February 2026.
- ^ a b c Giuliano Zirulia (2015). L'industria delle Medicine (in Italian). Edra. ISBN 9788821439049.
- ^ "Thierry Poiraud". Les Echos (in French). 4 March 2008. Retrieved 18 February 2026.
- ^ a b "Festa per i 20 anni in città del gruppo Menarini". Il Centro (in Italian). 3 December 2013. Retrieved 18 February 2026.
- ^ "Menarini Raunaq Pharma - Raunaq Group". Archived from the original on 18 May 2015. Retrieved 14 May 2015.
- ^ "Menarini e la Waterpolo Fiorentina, dietro c'è la storia farmaceutica di Firenze". Nove da Firenze (in Italian). 21 April 2011. Retrieved 18 February 2026.
- ^ "Menarini acquires Turkey's IE Ulagay". The Pharma Letter. 31 January 2001. Retrieved 18 February 2026.
- ^ "History / IE Ulagay - Menarini". Archived from the original on 18 May 2015. Retrieved 14 May 2015.
- ^ "Gemellaggio Firenze e Dresda, legami da arte a industria". ANSA (in Italian). 17 May 2018. Retrieved 18 February 2026.
- ^ Olga Mugnaini (4 September 2018). "Menarini, da Barcellona alla conquista del Brasile". La Nazione (in Italian). Retrieved 18 February 2026.
- ^ "Menarini alla conquista del mercato asiatico con 50 nuovi prodotti". AboutPharma (in Italian). 30 September 2013. Retrieved 18 February 2026.
- ^ "Menarini sbarca in Asia acquisito il Gruppo Invida". la Repubblica (in Italian). 15 November 2011. Retrieved 18 February 2026.
- ^ "Menarini acquisisce la start-up made in Italy Silicon Biosystems". AboutPharma (in Italian). 12 September 2013. Retrieved 18 February 2026.
- ^ "Tumori: Menarini compra americana CellSearch per ampliare biopsia". AGI (in Italian). 20 December 2016. Retrieved 18 February 2026.
- ^ "Menarini investe 100 milioni nella tecnologia per i vaccini" (in Italian).
- ^ a b "Menarini, l'azienda italiana cresciuta in Russia del 170%". ANSA (in Italian). 8 September 2019. Retrieved 27 February 2026.
- ^ "Eric Cornut Presidente Menarini" (in Italian).
- ^ "Eric Cornut: "Così farò entrare Menarini nell'Olimpo di Big Pharma"" (in Italian). 9 April 2018. Retrieved 13 August 2018.
- ^ "Menarini, Elcin Barker Ergun nominata Ceo". Il Messaggero (in Italian). 12 September 2019.
- ^ "Coronavirus: da Menarini kit per test rapidi in 20 minuti". ANSA. 2 April 2020.
- ^ "Gruppo Menarini, completata acquisizione di Stemline Therapeutics". Il Messaggero (in Italian). 10 June 2020. Retrieved 27 February 2026.
- ^ "Oncologia, farmaco Menarini approvato negli Stati Uniti". La Nazione (in Italian). 3 February 2023. Retrieved 27 February 2026.
- ^ "Neoplasia a cellule dendritiche plasmacitoidi blastiche, approvazione europea per tagraxofusp". Osservatorio Malattie Rare (in Italian). 2 February 2021. Retrieved 27 February 2026.
- ^ Fabrizia Maselli (3 October 2024). "Aifa approva selinexor di Menarini Stemline Italia per il mieloma multiplo". Milano Finanza (in Italian). Retrieved 27 February 2026.
- ^ Marco Landucci (21 December 2021). "Gruppo Menarini e Karyopharm Therapeutics: accordo per la commercializzazione di Nexpovio (selinexor)". Daily Health Industry (in Italian). Retrieved 27 February 2026.
- ^ "Farmaceutica, per il gruppo Menarini fatturato 2025 a 4,887 miliardi di euro: +6,2%". Sky TG24 (in Italian). 2026-03-06. Retrieved 2026-03-18.
- ^ Marini, Andrea (2024-04-01). "Menarini Biotech programma nuovi investimenti e assunzioni". Il Sole 24 Ore (in Italian). Retrieved 2026-03-18.
- ^ Testai, Leonardo (2026-03-06). "Cresce il fatturato 2025 di Menarini (che investe anche su Firenze)". T24 (in Italian). Retrieved 2026-03-18.
- ^ "Menarini on fire, fatturato a 4,9 miliardi di euro nel 2025, balzo del +6,2% sul 2024". RIF Day (in Italian). 2026-03-10. Retrieved 2026-04-28.
- ^ "Il gruppo Menarini acquista la ex Euticals di Casaletto". Il Cittadino (in Italian). 2016-05-23. Retrieved 2026-03-18.
- ^ "Farmaceutica. Menarini amplia la sede di Berlino e investe in Italia". Quotidiano Sanità (in Italian). 2016-09-06. Retrieved 2026-03-18.
- ^ "Lo stabilimento Menarini a Dresda". ANSA (in Italian). 2018-05-17. Retrieved 2026-03-18.
- ^ Landucci, Marco (2017-01-18). "Menarini cresce in Turchia e apre nuovo headquarter a Istanbul". Daily Health Industry (in Italian). Retrieved 2026-03-18.
- ^ "Menarini, record per fatturato consolidato: nel 2024 raggiunge 4,603 miliardi di euro" (in Italian). 2025-03-05. Retrieved 2026-03-18.
- ^ "Menarini accelera: record di crescita e sfida alle regole europee". Italia Informa (in Italian). 2025-03-05. Retrieved 2026-03-18.
- ^ "Menarini: la via all'internazionalizzazione è donna". Industria Italiana (in Italian). 2019-09-16. Retrieved 2026-03-18.
- ^ Diffidenti, Ernesto (2025-09-19). "Aleotti (Menarini): via il payback in Italia, contro i dazi serve uno scatto dell'Europa". Il Sole 24 Ore (in Italian). Retrieved 2025-11-19.
- ^ De Agostini, Manolo (2020-06-27). "Il cerotto digitale di Menarini permette di monitorare costantemente la glicemia". HWUpgrade (in Italian). Retrieved 2026-03-18.
- ^ "Menarini distribuisce il test che dà in 20 minuti il risultato Covid-2". la Repubblica (in Italian). 2020-04-02. Retrieved 2026-03-18.
- ^ "A Menarini Diagnostics Srl". Retrieved 2026-03-18.
- ^ Nadia Frulli (5 July 2017). "Menarini premia i Campioni di Fair Play". Arezzo Notizie (in Italian). Retrieved 18 March 2026.
- ^ "Al via la XXIII edizione Premio internazionale Fair Play Menarini". Quotidiano Sanità (in Italian). 17 June 2019. Retrieved 18 March 2026.
- ^ "Il Premio Internazionale Fair Play Menarini arriva a Firenze". Comune di Firenze (in Italian). 30 June 2022. Retrieved 18 March 2026.
- ^ "Premio Fair Play Menarini, sul palco anche Figo, Albertini e Tamberi". Sky TG24 (in Italian). 3 July 2025. Retrieved 18 November 2025.
- ^ "Arriva rete pediatri contro abusi bimbi, prima al mondo". la Repubblica (in Italian). 2016-05-12. Archived from the original on 8 June 2016. Retrieved 2026-06-05.
- ^ "15,000 doctors against child abuse - English". ANSA.it. 2016-05-12. Retrieved 2021-01-12.
- ^ "Minori: la rete anti-abuso di Menarini, Telefono Azzurro, pediatri Fimp, Sip e Aopi sbarca in Albania". AboutPharma (in Italian). 2016-10-18. Retrieved 2026-06-05.
- ^ Dieci alloggi Erp ristrutturati e assegnati grazie a Menarini
- ^ Consegnati i primi tre alloggi di edilizia popolare ristrutturati grazie a Menarini Archived 2016-12-20 at the Wayback Machine
- ^ Nazione, La (27 March 2014). "Case popolari: consegnati alloggi a sette famiglie". La Nazione (in Italian). Retrieved 2021-01-12.
- ^ Erp, Menarini ristruttura altri 10 alloggi. Potranno essere assegnati già nella primavera del 2015
- ^ Consegnati nel Quartiere 5 dieci alloggi Erp ad altrettante famiglie bisognose
- ^ Edilizia residenziale pubblica, Menarini ristruttura altri 10 alloggi popolari nei quartieri 4 e 5
- ^ Consegnati altri 10 alloggi ristrutturati da Menarini
- ^ "Menarini Group - Leave Russia". Leave Russia. Retrieved 2024-12-26.
- ^ "Corporate Responses to Sanctions Against Russia". Leave Russia. Retrieved 2024-12-26.